Christopher Morabito

Christopher Morabito (senior executive) discloses dealings in 2 companies, chiefly Astria Therapeutics, Inc. and Fulcrum Therapeutics, Inc. In total, 6 filings cover trades dated from 28 June 2021 to 1 April 2024.

Both buying and selling appear: 1 purchase worth €8,447, against 2 sales worth €103k. Sales outweigh purchases by €94k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 3 option exercises. So far in 2024, the count stands at no purchases and 2 sales.

The latest filing, published on 3 April 2024, reports an option exercise of €36k in Astria Therapeutics, Inc. The last insider purchase was made public on 29 June 2021, 1,937 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.